Compare TMDX & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMDX | BCRX |
|---|---|---|
| Founded | 1998 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.3B |
| IPO Year | 2019 | 1995 |
| Metric | TMDX | BCRX |
|---|---|---|
| Price | $66.78 | $8.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 11 |
| Target Price | ★ $148.22 | $20.82 |
| AVG Volume (30 Days) | 1.8M | ★ 4.7M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 382.18 | 381.40 |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $605,494,000.00 | $25,186,000.00 |
| Revenue This Year | $24.25 | N/A |
| Revenue Next Year | $18.75 | $12.55 |
| P/E Ratio | $341.18 | ★ N/A |
| Revenue Growth | ★ 37.13 | N/A |
| 52 Week Low | $60.11 | $6.00 |
| 52 Week High | $156.00 | $11.31 |
| Indicator | TMDX | BCRX |
|---|---|---|
| Relative Strength Index (RSI) | 31.32 | 49.90 |
| Support Level | $60.11 | $8.89 |
| Resistance Level | $120.60 | $10.04 |
| Average True Range (ATR) | 3.81 | 0.42 |
| MACD | 1.43 | 0.01 |
| Stochastic Oscillator | 61.30 | 47.08 |
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.